Literature DB >> 9519892

Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization.

R Cheingsong-Popov1, S Osmanov, C P Pau, G Schochetman, F Barin, H Holmes, G Francis, H Ruppach, U Dietrich, S Lister, J Weber.   

Abstract

V3 serotyping refers to a system based on binding of antibody in patient sera to V3-loop peptides derived from HIV-1 env genetic subtypes. The V3x serotype represents reactivity of serum from an HIV-1-infected patient (regardless of viral genetic subtype), which reacts preferentially to a V3 peptide derived from the X subtype sequence. We have classified HIV-1 serotypes, determined the relationship between the HIV-1 V3 serotypes and viral genetic subtypes in a large study (n = 125), and evaluated the performance of three different V3 peptide-binding assays. Seven HIV-1 V3 serotypes were identified: A, B, B-Br, B-Th, C, D, and E. Serotypes B-Br and B-Th represent sera that react specifically to peptides derived from Brazilian B (B-Br, GWGR) and Thai B (B-Th, GPGQ) strains. The HIV-1 V3 B, C, and E serotypes correlated closely with their viral env genetic subtypes; 19-26 of 32 B sera (59-79%), 3-4 of 4 C sera (75-100%), and 19-22 of 23 E sera (83-96%) were identified as serotypes B, C, and E, respectively. In contrast, two major V3 serotypes were classified in A sera: A (14-18 of 36 [40-50%]) and C (12-19 of 36 [33-54%]). Similarly, two major V3 serotypes were classified in D sera: B (6-10 of 20 [30-50%]) and D (9-12 of 20 [45-60%]). Serotyping of subtype E sera showed the best concordance with genetic subtypes by all assays. Overall, HIV-1 V3 serotyping produced consistent results among three laboratories. However, HIV-1 V3 serotypes do not distinguish all HIV-1 genetic subtypes. The relative biological significance of the V3 serotypes remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519892     DOI: 10.1089/aid.1998.14.311

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants.

Authors:  W H Koch; P S Sullivan; C Roberts; K Francis; R Downing; T D Mastro; J Nkengasong; D Hu; S Masciotra; C Schable; R B Lal
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 2.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG.

Authors:  M P de Baar; E C Timmermans; M Bakker; E de Rooij; B van Gemen; J Goudsmit
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

5.  V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant.

Authors:  J C Plantier; F Damond; S Souquières; F Brun-Vézinet; F Simon; F Barin
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

6.  Diagnosis of human immunodeficiency virus type 1 infection with different subtypes using rapid tests.

Authors:  S Phillips; T C Granade; C P Pau; D Candal; D J Hu; B S Parekh
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

7.  Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors:  N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Application of dried blood spot specimens for serologic subtyping of human immunodeficiency virus type 1 in Thailand.

Authors:  P Chanbancherd; A E Brown; R Trichavaroj; P Tienamporn; P Puthakird; N Limpairojn; T C VanCott; M S de Souza
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

Authors:  Zehava Grossman; Ellen E Paxinos; Diana Averbuch; Shlomo Maayan; Neil T Parkin; Dan Engelhard; Margalit Lorber; Valery Istomin; Yael Shaked; Ella Mendelson; Daniela Ram; Chris J Petropoulos; Jonathan M Schapiro
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Authors:  Sarah C Ball; Awet Abraha; Kalonji R Collins; Andre J Marozsan; Heather Baird; Miguel E Quiñones-Mateu; Adam Penn-Nicholson; Michael Murray; Nathalie Richard; Michael Lobritz; Peter A Zimmerman; Tatsuyoshi Kawamura; Andrew Blauvelt; Eric J Arts
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.